Atrial Fibrillation Guidelines Updated

Published Online: Thursday, April 10, 2014
Follow Pharmacy_Times:
The American Heart Association, American College of Cardiology, and Heart Rhythm Society have updated their guidelines on management of atrial fibrillation. The new guidelines include recommendations regarding use of new oral anticoagulants—dabigatran, rivaroxaban, and apixaban—as well as warfarin. However, the guidelines do not specify preferences among the 3 new oral anticoagulants due to a lack of head-to-head trials and note that treatment decisions should be based on concerns including risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics. The guidelines will be published in the Journal of the American College of Cardiology, Circulation, Journal of the American Heart Association, and Heart Rhythm.

To read more about the new guidelines on HCPLive, click here.
Related Articles
As the 2015 American College of Cardiology Annual Scientific Session and Expo concludes, take a look at a few of the latest discoveries that were presented at the conference.
Warfarin has been used for over half a century, and its interactions with other drugs have been exhaustively investigated.
Boehringer Ingelheim recently submitted a biologics license application to the FDA requesting accelerated approval of its investigational drug, idarucizumab, for the rapid reversal of anticoagulant effects of dabigatran (Pradaxa).
Health-system pharmacists may see an increasing threat of active shooter situations in their hospitals.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$